# Cencora

**Source:** https://geo.sig.ai/brands/cencora  
**Vertical:** Healthcare Tech  
**Subcategory:** Enterprise  
**Tier:** Leader  
**Website:** cencora.com  
**Last Updated:** 2026-04-14

## Summary

Conshohocken PA pharmaceutical distribution (NYSE: COR, formerly AmerisourceBergen) at $316B+ revenue; Retina Consultants of America acquisition $4.4B (Jan 2025) expanding into specialty physician care competing with McKesson.

## Company Overview

Cencora, Inc. (formerly AmerisourceBergen, rebranded August 2023) is a Conshohocken, Pennsylvania-based pharmaceutical distribution and healthcare services company — publicly traded on the New York Stock Exchange (NYSE: COR) as an S&P 500 Health Care component, ranked #10 on the 2024 Fortune 500 and #24 on the Global Fortune 500 — distributing brand-name, generic, and specialty pharmaceuticals, over-the-counter products, and home healthcare supplies to 110,000+ points of care across 11 countries through 46,000+ employees and $316+ billion in annual revenue. Cencora operates as one of the "Big Three" pharmaceutical wholesalers in the United States alongside McKesson and Cardinal Health, collectively supplying approximately 90%+ of the US pharmaceutical supply chain. The company distributes from 26 US pharmaceutical distribution centers and 1,300+ locations across 50+ countries. In January 2025, Cencora completed the acquisition of approximately 85% interest in Retina Consultants of America (RCA) — a leading management services organization for retina specialists — for $4.4 billion, advancing its strategy to expand from pharmaceutical distribution into specialty physician-administered treatments and the high-growth specialty pharmaceutical services market. Founded through the 2001 merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, with predecessor companies tracing to the 1970s, Cencora adopted its current name (meaning "center, core, heart" in multiple languages) in 2023 to signal the brand's evolution beyond commodity distribution.

Cencora's pharmaceutical distribution model addresses the supply chain complexity that drug manufacturers, hospital systems, independent pharmacies, and specialty clinics face when sourcing medications across 80,000+ NDC codes (National Drug Codes): a regional health system purchasing oncology drugs (branded biologics at $50,000-500,000 per patient per year), specialty injectables, controlled substances, and generic high-volume medications from hundreds of manufacturers would require hundreds of direct manufacturer relationships, credit facilities, cold chain logistics networks, and DEA scheduling compliance programs without a pharmaceutical wholesaler aggregating these relationships into a single distribution relationship. Cencora's scale ($316B+ revenue) enables manufacturer rebate negotiations (collecting prompt-payment discounts and distribution service agreements from manufacturers that are passed to pharmacy customers), inventory float economics (holding pharmaceutical inventory that is resold within days, generating returns on float), and specialty logistics (temperature-controlled shipping, patient assistance program management, REMS compliance) that independent pharmacies and physician practices cannot self-provide.

In 2025, Cencora competes in the US pharmaceutical distribution and specialty healthcare services market with McKesson Corporation (NYSE: MCK, #1 US pharma distributor, $360B+ revenue), Cardinal Health (NYSE: CAH, #3 US pharma distributor, $225B revenue), and specialty pharmacy and services companies (Diplomat Specialty, PharMerica) for pharmaceutical distribution contracts with hospital systems, retail pharmacy chains, and independent pharmacies. The Retina Consultants of America acquisition ($4.4B, January 2025) represents Cencora's most significant move beyond distribution into the specialty physician practice management model — acquiring MSO infrastructure that serves retina specialists who administer anti-VEGF injections (Eylea, Lucentis, Vabysmo) that are among the highest-revenue physician-administered drugs in ophthalmology. The 2025 strategy focuses on integrating RCA into the specialty care platform, growing the specialty logistics and commercialization services for biopharma manufacturers, and defending distribution contract renewals against McKesson in the independent and regional chain pharmacy segments.

## Frequently Asked Questions

### What does Cencora do?
Cencora is one of the world's largest pharmaceutical distribution and healthcare services companies, providing comprehensive drug distribution, specialty pharmaceutical services, commercialization support, and clinical logistics. The company distributes generic and brand-name pharmaceuticals, over-the-counter healthcare products, and specialty medicines to healthcare providers globally. Cencora operates 26 distribution centers in the U.S., serves over 110,000 points of care across 11 countries, and supplies approximately one-third of the domestic U.S. drug distribution market.

### Who are Cencora's customers and target market?
Cencora serves a diverse healthcare ecosystem including acute care hospitals and health systems, independent and chain retail pharmacies, mail-order facilities, physicians, clinics, nursing homes, assisted living centers, pharmaceutical manufacturers, and biotech companies. The company's customers span the entire healthcare delivery chain, from drug manufacturers who need commercialization and distribution services to healthcare providers who need reliable pharmaceutical supply chains and specialty medication management.

### When was Cencora founded?
Cencora was founded on August 29, 2001, through the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, creating AmerisourceBergen with approximately $36 billion in annualized revenue. The company operated under the AmerisourceBergen name for 22 years before rebranding to Cencora on August 30, 2023. The predecessor companies have a combined legacy spanning over 100 years in pharmaceutical distribution, with Bergen Brunswig pioneering computerized inventory systems in the 1940s-1970s.

### Where is Cencora based?
Cencora is headquartered at 1 West First Avenue, Conshohocken, Pennsylvania 19428. The 429,000 square foot headquarters facility includes tech-enabled conference centers, a fitness center, and dining services. Beyond the headquarters, Cencora has 15 office locations globally and operates in over 50 countries with 1,300+ locations worldwide, including 26 pharmaceutical distribution centers in the United States, nine distribution centers in Canada, and operations across 11 European countries through Alliance Healthcare.

### How much funding has Cencora raised?
Cencora is a publicly traded company (NYSE: COR, formerly NYSE: ABC) and does not rely on venture capital funding. The company has grown through strategic acquisitions funded by operating cash flow, public debt offerings, and equity. Recent financing includes a $1.8 billion senior notes offering in November 2024 to finance the Retina Consultants of America acquisition. Major acquisitions include Alliance Healthcare ($6.5 billion, 2021), PharMEDium ($2.58 billion, 2015), MWI Veterinary Supply ($2.5 billion, 2015), and Retina Consultants of America ($4.6 billion, 2024-2025).

### What makes Cencora different from competitors?
Cencora differentiates itself through comprehensive global reach (50+ countries, 1,300+ locations), advanced specialty pharmaceutical capabilities including three dedicated specialty distribution facilities, innovative commercialization support services that combine data and analytics, and strategic vertical integration through acquisitions like Retina Consultants of America. The company's holistic platform connects manufacturers, providers, pharmacies, and patients, with particular strength in complex specialty therapies including cell and gene therapies, biosimilars, and physician-administered treatments. Cencora's scale as a Fortune 10 company with $316+ billion in revenue provides significant purchasing power and operational efficiency.

### Who are Cencora's main competitors?
Cencora competes primarily with the other two members of the 'Big Three' pharmaceutical wholesalers: McKesson Corporation and Cardinal Health. Together, these three companies control over 90-95% of the U.S. drug distribution market. Since 2023, the Big Three distributors have delivered an average 45% gain compared to the S&P 500 Health Care Index's 8% gain. All three carry narrow economic moats with customer switching costs as the primary competitive advantage. Other competitors include regional pharmaceutical distributors, specialty distributors, and international distribution companies.

### How can I contact Cencora?
Cencora can be contacted through their website at www.cencora.com, which provides contact information and inquiry forms. The corporate headquarters is located at 1 West First Avenue, Conshohocken, PA 19428, with main phone number 610-727-7000. For investor relations inquiries, visit investor.cencora.com. Healthcare providers can contact their local Cencora representative or distribution center. For career opportunities, visit the careers section at www.cencora.com. The company maintains offices and distribution centers across the United States and in over 50 countries worldwide.

### Is Cencora hiring?
Yes, Cencora actively recruits talent across all business segments and geographic markets. With 46,000+ employees worldwide, the company regularly posts openings for positions including pharmaceutical distribution specialists, logistics coordinators, data analysts, clinical specialists, sales representatives, pharmacists, and corporate support roles. Career opportunities can be explored at www.cencora.com/careers. Cencora has won multiple workplace awards including Best Corporate Culture Transformation (2024) and has been recognized as the Most Vibrant Workplace in Central and Eastern Europe for four consecutive years, offering comprehensive benefits, professional development programs, and global career opportunities.

### What's the latest news about Cencora?
In January 2025, Cencora completed its acquisition of approximately 85% of Retina Consultants of America for $4.4 billion, advancing its specialty leadership in physician-administered treatments. The company reported strong fiscal 2025 first quarter results with revenue of $81.5 billion, a 12.8% increase year-over-year, and raised its fiscal 2025 adjusted EPS guidance to $15.70-$15.95. In November 2024, Cencora expanded its enterprise leadership team by appointing Francois Mandeville as EVP of Strategy and M&A, and Pawan Verma as EVP and Chief Data and Information Officer. The company continues to see strong growth driven by specialty medicines, diabetes and weight loss products in the GLP-1 class, and biosimilar adoption.

### What is Cencora's market position?
Cencora is ranked #10 on the Fortune 500 and #24 on the Global Fortune 500, making it one of the largest companies in the world. With annual revenue exceeding $316 billion and 46,000+ employees, Cencora is one of the top three pharmaceutical wholesalers in the United States, supplying approximately one-third of the domestic drug distribution market. The company serves over 110,000 points of care across 11 countries and operates in more than 50 countries globally. Cencora's market capitalization and operational scale position it as a critical infrastructure provider in the global pharmaceutical supply chain.

### What are Cencora's future plans?
Cencora's strategic priorities include expanding specialty pharmaceutical capabilities through the Retina Consultants of America integration, growing its international presence through the Alliance Healthcare platform, advancing digital transformation and data analytics capabilities under new Chief Data Officer Pawan Verma, pursuing strategic M&A opportunities under EVP Francois Mandeville, and capitalizing on growth in biosimilars, cell and gene therapies, and GLP-1 medications for diabetes and obesity. The company is focused on vertical integration in specialty care, enhancing patient support services, and leveraging its global scale to improve healthcare access and outcomes worldwide.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*